These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 19397417)

  • 1. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.
    Barrett PN; Mundt W; Kistner O; Howard MK
    Expert Rev Vaccines; 2009 May; 8(5):607-18. PubMed ID: 19397417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous cell lines as a production system for influenza vaccines.
    Genzel Y; Reichl U
    Expert Rev Vaccines; 2009 Dec; 8(12):1681-92. PubMed ID: 19943763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suspension-Vero cell cultures as a platform for viral vaccine production.
    Paillet C; Forno G; Kratje R; Etcheverrigaray M
    Vaccine; 2009 Oct; 27(46):6464-7. PubMed ID: 19559123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of MDCK cells for production of live attenuated influenza vaccine.
    Liu J; Shi X; Schwartz R; Kemble G
    Vaccine; 2009 Oct; 27(46):6460-3. PubMed ID: 19559113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.
    Ehrlich HJ; Müller M; Fritsch S; Zeitlinger M; Berezuk G; Löw-Baselli A; van der Velden MV; Pöllabauer EM; Maritsch F; Pavlova BG; Tambyah PA; Oh HM; Montomoli E; Kistner O; Noel Barrett P
    J Infect Dis; 2009 Oct; 200(7):1113-8. PubMed ID: 19712040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.
    Montomoli E; Khadang B; Piccirella S; Trombetta C; Mennitto E; Manini I; Stanzani V; Lapini G
    Expert Rev Vaccines; 2012 May; 11(5):587-94. PubMed ID: 22827244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The present status of rabies vaccine development and clinical experience with rabies vaccine.
    Roumiantzeff M
    Southeast Asian J Trop Med Public Health; 1988 Dec; 19(4):549-61. PubMed ID: 3070767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel mammalian cell (Vero) derived influenza virus vaccine: development, characterization and industrial scale production.
    Kistner O; Barrett PN; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
    Wien Klin Wochenschr; 1999 Mar; 111(5):207-14. PubMed ID: 10226351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line.
    Montagnon BJ
    Dev Biol Stand; 1989; 70():27-47. PubMed ID: 2759353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematically experimental investigation on carcinogenesis or tumorigenicity of VERO cell lines of different karyotypes in nude mice in vivo used for viral vaccine manufacture.
    Zhang DL; Ji L; Li LJ; Huang GS
    Yi Chuan Xue Bao; 2004 Jul; 31(7):647-60. PubMed ID: 15473315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on a purified and inactivated Japanese encephalitis vaccine prepared on Vero cells using SA14-14-2 attenuated virus strain].
    Yao Z; Dong G; Yu Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Jun; 13(2):191-3. PubMed ID: 12569794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preparation of vero cell-adapted influenza H5N1 virus strain by genetic reassortment].
    Shen J; Sun MB; Ma L; Song SH; Li WD; Jiang SD; Yang JS; Liao GY
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Apr; 24(2):119-21. PubMed ID: 21110431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.
    Barrett PN; Terpening SJ; Snow D; Cobb RR; Kistner O
    Expert Rev Vaccines; 2017 Sep; 16(9):883-894. PubMed ID: 28724343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus.
    Tiwari M; Parida M; Santhosh SR; Khan M; Dash PK; Rao PV
    Vaccine; 2009 Apr; 27(18):2513-22. PubMed ID: 19368794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro potency assay for yellow fever vaccines: comparison of three vero cell lines sources.
    Fournier-Caruana J; Poirier B; Garnier F; Fuchs F
    Biologicals; 2000 Mar; 28(1):33-40. PubMed ID: 10799054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of virus yield as a strategy to improve rabies vaccine production by Vero cells in a bioreactor.
    Trabelsi K; Rourou S; Loukil H; Majoul S; Kallel H
    J Biotechnol; 2006 Jan; 121(2):261-71. PubMed ID: 16153733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Vero cell-derived influenza whole virus vaccine.
    Kistner O; Barrett PN; Mundt W; Reiter M; Schober-Bendixen S; Eder G; Dorner F
    Dev Biol Stand; 1999; 98():101-10; discussion 111. PubMed ID: 10494963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Passage adaptability of candidate strains for hemorrhagic fever with renal syndrome purified vaccine in Vero cells and their immunogenicity].
    Chen W; Xue CF; Liu JQ; Li ZY; Fan YX; Xu L; Liao H
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Jun; 17(2):129-32. PubMed ID: 12869992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New viral vaccines.
    Arvin AM; Greenberg HB
    Virology; 2006 Jan; 344(1):240-9. PubMed ID: 16364754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics.
    Koudstaal W; Hartgroves L; Havenga M; Legastelois I; Ophorst C; Sieuwerts M; Zuijdgeest D; Vogels R; Custers J; de Boer-Luijtze E; de Leeuw O; Cornelissen L; Goudsmit J; Barclay W
    Vaccine; 2009 Apr; 27(19):2588-93. PubMed ID: 19428865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.